Homepage Top Section2

The platform can detect unintended pH changes, bolster formulation stability, and lower viscosity for ensuring efficacy and maximising delivery of drugs. S-HiCon incorporates a preliminary ‘concentration gate check’

The CRDAC’s positive vote is a pivotal step towards the potential approval of elamipretide, a first-in-class mitochondria-targeted therapy. The committee concluded with a 10 to 6 vote that

The drug is under evaluation in Phase IIb studies for both primary sclerosing cholangitis under the VISTAS study and PBC under the VANTAGE study. This milestone is based on the

This collaboration will focus on developing new medicines for conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD), utilising targets identified by insitro’s AI/ML-based platform. The new partnership

On receipt of approval, this asset could become the first disease-modifying therapy for ALS, focusing on immunologic mechanisms rather than neurologic. A sodium chlorite infusion, NP001 has been

A decision from the US regulator is expected by the first quarter of 2025. The sNDA for Calquence is being assessed by the FDA under Project Orbis, an

This programme is designed to expedite the development and review of new therapies targeting serious or life-threatening conditions by demonstrating the potential to address unmet medical needs. A

This application aims to provide a new treatment option for adult patients who have priorly treated, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is epidermal

Sabirnetug is a humanised monoclonal antibody that has shown selective target engagement with toxic soluble amyloid beta (Aβ) oligomers in patients with AD. The partnership between Acumen and